Azeliragon trial for pancreatic cancer after prior treatments failed
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests azeliragon in people whose pancreatic cancer has spread or grown locally and who did not respond well to earlier chemotherapy. It aims to see whether the drug can help control the cancer and be tolerated after prior treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have pancreatic cancer that is confirmed by biopsy (adenocarcinoma) and cannot be cured with surgery or similar curative steps
- You previously received either gemcitabine plus Abraxane or FOLFIRINOX chemotherapy
- Your prior chemotherapy side effects (other than hair loss) have mostly improved back to mild levels or your baseline symptoms are stable
- Your blood tests are strong enough (enough white blood cells, platelets, and hemoglobin) and your liver and kidney tests are within required ranges
- You are able to do daily activities at a limited level (ECOG 0 to 2), and you can take oral study medicine as instructed
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests how well olaptesed plus pembrolizumab works with irinotecan or with gemcitabine plus nab-paclitaxel in people with metastatic pancreatic cancer that keeps growing after standard first treatment. It may help control the cancer by changing how the body fights tumors and by delivering chemotherapy differently.
This trial tests whether adding Gembrax (a combination that includes gemcitabine and nab-paclitaxel) before standard FOLFIRINOX works better than FOLFIRINOX alone in people with pancreatic cancer that has already spread. It looks at whether this “step-up first” approach improves results and is still tolerable.
This trial tests a new combination of three drugs (QL1706, chidamide, and AG) as the very first treatment for people with metastatic pancreatic cancer. The goal is to see if this combination is safe and effective, and it may offer a new option for those who have not had any prior therapy.
This trial tests a combination of three chemotherapy drugs (mFOLFIRINOX) along with anlotinib (a targeted therapy) and sintilimab (an immunotherapy) for people with advanced pancreatic cancer who have not had prior treatment. The goal is to see if this combination can help shrink tumors or slow the disease.
This trial tests a combination of four drugs (surufatinib, camrelizumab, nab-paclitaxel, and gemcitabine) as a first treatment for people whose pancreatic cancer has spread to other parts of the body. The goal is to see if this combination helps shrink tumors and improve survival.
This trial tests a combination of three drugs—capecitabine (a chemotherapy pill), camrelizumab (an immunotherapy), and apatinib (a targeted therapy)—for people with advanced pancreatic cancer whose previous treatment stopped working or who cannot tolerate standard chemotherapy.
Hear when a new Metastatic Pancreatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.